WallStSmart

China Pharma Holdings Inc (CPHI)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 325179% more annual revenue ($14.30B vs $4.40M). VTRS leads profitability with a -24.6% profit margin vs -83.2%. VTRS appears more attractively valued with a PEG of 0.14. VTRS earns a higher WallStSmart Score of 50/100 (C-).

CPHI

Hold

47

out of 100

Grade: D+

Growth: 4.0Profit: 2.0Value: 6.7Quality: 5.0

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.80

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CPHI2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1610/10

Growing faster than its price suggests

Price/BookValuation
0.2x10/10

Reasonable price relative to book value

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

CPHI4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$4.96M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-52.7%2/10

ROE of -52.7% — below average capital efficiency

Free Cash FlowQuality
$-237,6002/10

Negative free cash flow — burning cash

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-21.1%2/10

ROE of -21.1% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-24.6%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : CPHI

The strongest argument for CPHI centers on PEG Ratio, Price/Book. Revenue growth of 10.9% demonstrates continued momentum. PEG of 0.16 suggests the stock is reasonably priced for its growth.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : CPHI

The primary concerns for CPHI are EPS Growth, Market Cap, Return on Equity.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

CPHI carries more volatility with a beta of 1.04 — expect wider price swings.

CPHI is growing revenue faster at 10.9% — sustainability is the question.

VTRS generates stronger free cash flow (551M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VTRS scores higher overall (50/100 vs 47/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

China Pharma Holdings Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · China

China Pharma Holdings, Inc. develops, manufactures and markets generic and branded pharmaceutical and biochemical products primarily for hospitals and private retailers in the People's Republic of China. The company is headquartered in Haikou, the People's Republic of China.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?